{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:09:40Z","timestamp":1790251780993,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41375-026-03064-4","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T07:51:41Z","timestamp":1784188301000},"page":"2167-2180","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rbm5 sustains leukemia stem cells through a Myc-driven transcriptional circuitry"],"prefix":"10.1038","volume":"40","author":[{"given":"Mengli","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaela","family":"Fields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9779-6225","authenticated-orcid":false,"given":"Jianfeng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0099-858X","authenticated-orcid":false,"given":"Beisi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6312-3863","authenticated-orcid":false,"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5938-5510","authenticated-orcid":false,"given":"Chunliang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7573-4813","authenticated-orcid":false,"given":"Peng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"3064_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11:41.","journal-title":"Blood Cancer J"},{"key":"3064_CR2","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","volume":"392","author":"NJ Short","year":"2018","unstructured":"Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392:593\u2013606.","journal-title":"Lancet"},{"key":"3064_CR3","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059\u201374.","DOI":"10.1056\/NEJMoa1301689"},{"key":"3064_CR4","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209\u201321.","journal-title":"N Engl J Med"},{"key":"3064_CR5","doi-asserted-by":"publisher","first-page":"7026","DOI":"10.1200\/JCO.2022.40.16_suppl.7026","volume":"40","author":"D Nguyen","year":"2022","unstructured":"Nguyen D, Ning J, Qiao W, Sasaki K, Kantarjian HM, Short NJ, et al. Acute myeloid leukemia with KMT2Ar and association with risk of bleeding and early mortality. J Clin Oncol. 2022;40:7026.","journal-title":"J Clin Oncol"},{"key":"3064_CR6","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ccr.2008.10.001","volume":"14","author":"AV Krivtsov","year":"2008","unstructured":"Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU, et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell. 2008;14:355\u201368.","journal-title":"Cancer Cell"},{"key":"3064_CR7","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1158\/2159-8290.CD-22-0424","volume":"13","author":"XQD Wang","year":"2023","unstructured":"Wang XQD, Fan D, Han Q, Liu Y, Miao H, Wang X, et al. Mutant NPM1 hijacks transcriptional hubs to maintain pathogenic gene programs in acute myeloid leukemia. Cancer Discov. 2023;13:724\u201345.","journal-title":"Cancer Discov"},{"key":"3064_CR8","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1158\/2159-8290.CD-22-0366","volume":"13","author":"HJ Uckelmann","year":"2023","unstructured":"Uckelmann HJ, Haarer EL, Takeda R, Wong EM, Hatton C, Marinaccio C, et al. Mutant NPM1 directly regulates oncogenic transcription in acute myeloid leukemia. Cancer Discov. 2023;13:746\u201365.","journal-title":"Cancer Discov"},{"key":"3064_CR9","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135:2137\u201345.","journal-title":"Blood"},{"key":"3064_CR10","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381:1728\u201340.","journal-title":"N Engl J Med"},{"key":"3064_CR11","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329.","journal-title":"N Engl J Med"},{"key":"3064_CR12","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","volume":"20","author":"JE Cortes","year":"2019","unstructured":"Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019;20:984\u201397.","journal-title":"Lancet Oncol"},{"key":"3064_CR13","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","volume":"615","author":"F Perner","year":"2023","unstructured":"Perner F, Stein EM, Wenge DV, Singh S, Kim J, Apazidis A, et al. MEN1 mutations mediate clinical resistance to menin inhibition. Nature. 2023;615:913\u20139.","journal-title":"Nature"},{"key":"3064_CR14","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","volume":"615","author":"GC Issa","year":"2023","unstructured":"Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023;615:920\u20134.","journal-title":"Nature"},{"key":"3064_CR15","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1182\/blood-2016-10-696039","volume":"129","author":"DA Pollyea","year":"2017","unstructured":"Pollyea DA, Jordan CT. Therapeutic targeting of acute myeloid leukemia stem cells. Blood. 2017;129:1627\u201335.","journal-title":"Blood"},{"key":"3064_CR16","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/nature04980","volume":"442","author":"AV Krivtsov","year":"2006","unstructured":"Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006;442:818\u201322.","journal-title":"Nature"},{"key":"3064_CR17","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1182\/blood-2016-10-696054","volume":"129","author":"D Thomas","year":"2017","unstructured":"Thomas D, Majeti R. Biology and relevance of human acute myeloid leukemia stem cells. Blood. 2017;129:1577\u201385.","journal-title":"Blood"},{"key":"3064_CR18","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41568-019-0230-9","volume":"20","author":"D Vetrie","year":"2020","unstructured":"Vetrie D, Helgason GV, Copland M. The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. Nat Rev Cancer. 2020;20:158\u201373.","journal-title":"Nat Rev Cancer"},{"key":"3064_CR19","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ccell.2019.01.010","volume":"35","author":"E Wang","year":"2019","unstructured":"Wang E, Lu SX, Pastore A, Chen X, Imig J, Chun-Wei Lee S, et al. Targeting an RNA-binding protein network in acute myeloid leukemia. Cancer Cell. 2019;35:369\u201384.e7.","journal-title":"Cancer Cell"},{"key":"3064_CR20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ccell.2020.04.017","volume":"38","author":"R Su","year":"2020","unstructured":"Su R, Dong L, Li Y, Gao M, Han L, Wunderlich M, et al. Targeting FTO suppresses cancer stem cell maintenance and immune evasion. Cancer Cell. 2020;38:79\u201396.e11.","journal-title":"Cancer Cell"},{"key":"3064_CR21","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.stem.2020.12.005","volume":"28","author":"E Wang","year":"2021","unstructured":"Wang E, Zhou H, Nadorp B, Cayanan G, Chen X, Yeaton AH, et al. Surface antigen-guided CRISPR screens identify regulators of myeloid leukemia differentiation. Cell Stem Cell. 2021;28:718\u201331.e6.","journal-title":"Cell Stem Cell"},{"key":"3064_CR22","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s43018-020-0054-2","volume":"1","author":"J Bajaj","year":"2020","unstructured":"Bajaj J, Hamilton M, Shima Y, Chambers K, Spinler K, Van Nostrand EL, et al. An in vivo genome-wide CRISPR screen identifies the RNA-binding protein Staufen2 as a key regulator of myeloid leukemia. Nat Cancer. 2020;1:410\u201322.","journal-title":"Nat Cancer"},{"key":"3064_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31155-0","volume":"13","author":"L Liu","year":"2022","unstructured":"Liu L, Vujovic A, Deshpande NP, Sathe S, Anande G, Chen HTT, et al. The splicing factor RBM17 drives leukemic stem cell maintenance by evading nonsense-mediated decay of pro-leukemic factors. Nat Commun. 2022;13:3833.","journal-title":"Nat Commun"},{"key":"3064_CR24","doi-asserted-by":"publisher","first-page":"3542","DOI":"10.1038\/s41375-021-01328-9","volume":"35","author":"DP Steensma","year":"2021","unstructured":"Steensma DP, Wermke M, Klimek VM, Greenberg PL, Font P, Komrokji RS, et al. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia. 2021;35:3542\u201350.","journal-title":"Leukemia"},{"key":"3064_CR25","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abj8357","volume":"8","author":"C Han","year":"2022","unstructured":"Han C, Khodadadi-Jamayran A, Lorch AH, Jin Q, Serafin V, Zhu P, et al. SF3B1 homeostasis is critical for survival and therapeutic response in T cell leukemia. Sci Adv. 2022;8:eabj8357.","journal-title":"Sci Adv"},{"key":"3064_CR26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.cell.2019.06.001","volume":"178","author":"R Xiao","year":"2019","unstructured":"Xiao R, Chen J-Y, Liang Z, Luo D, Chen G, Lu ZJ, et al. Pervasive chromatin-RNA binding protein interactions enable RNA-based regulation of transcription. Cell. 2019;178:107\u201321.e18.","journal-title":"Cell"},{"key":"3064_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-023-03149-8","volume":"25","author":"M Zhang","year":"2024","unstructured":"Zhang M, Hyle J, Chen XX, Xin Y, Jin Y, Zhang J, et al. RNA-binding protein RBM5 plays an essential role in acute myeloid leukemia by activating the oncogenic protein HOXA9. Genome Biol. 2024;25:16.","journal-title":"Genome Biol"},{"key":"3064_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-024-03242-6","volume":"25","author":"X Du","year":"2024","unstructured":"Du X, Qin W, Yang C, Dai L, San M, Xia Y, et al. RBM22 regulates RNA polymerase II 5\u2019 pausing, elongation rate, and termination by coordinating 7SK-P-TEFb complex and SPT5. Genome Biol. 2024;25:102.","journal-title":"Genome Biol"},{"key":"3064_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/hem3.116","volume":"8","author":"P Joshi","year":"2024","unstructured":"Joshi P, Keyvani Chahi A, Liu L, Moreira S, Vujovic A, Hope KJ. RNA binding protein-directed control of leukemic stem cell evolution and function. HemaSphere. 2024;8:1\u201322.","journal-title":"HemaSphere"},{"key":"3064_CR30","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nature09171","volume":"466","author":"T Ito","year":"2010","unstructured":"Ito T, Kwon HY, Zimdahl B, Congdon KL, Blum J, Lento WE, et al. Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature. 2010;466:765\u20138.","journal-title":"Nature"},{"key":"3064_CR31","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/nm.2187","volume":"16","author":"MG Kharas","year":"2010","unstructured":"Kharas MG, Lengner CJ, Al-Shahrour F, Bullinger L, Ball B, Zaidi S, et al. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med. 2010;16:903\u20138.","journal-title":"Nat Med"},{"key":"3064_CR32","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1182\/blood-2011-04-346767","volume":"118","author":"RJ Byers","year":"2011","unstructured":"Byers RJ, Currie T, Tholouli E, Rodig SJ, Kutok JL. MSI2 protein expression predicts unfavorable outcome in acute myeloid leukemia. Blood. 2011;118:2857\u201367.","journal-title":"Blood"},{"key":"3064_CR33","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/ng.3854","volume":"49","author":"LP Vu","year":"2017","unstructured":"Vu LP, Prieto C, Amin EM, Chhangawala S, Krivtsov A, Calvo-Vidal MN, et al. Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells. Nat Genet. 2017;49:866\u201375.","journal-title":"Nat Genet"},{"key":"3064_CR34","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s43018-021-00220-w","volume":"2","author":"C Prieto","year":"2021","unstructured":"Prieto C, Nguyen DTTT, Liu Z, Wheat J, Perez A, Gourkanti S, et al. Transcriptional control of CBX5 by the RNA-binding proteins RBMX and RBMXL1 maintains chromatin state in myeloid leukemia. Nat Cancer. 2021;2:741\u201357.","journal-title":"Nat Cancer"},{"key":"3064_CR35","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/JTO.0b013e3181c6e330","volume":"5","author":"LC Sutherland","year":"2010","unstructured":"Sutherland LC, Wang K, Robinson AG. RBM5 as a putative tumor suppressor gene for lung cancer. J Thorac Oncol. 2010;5:294\u20138.","journal-title":"J Thorac Oncol"},{"key":"3064_CR36","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nature20598","volume":"540","author":"SWK Ng","year":"2016","unstructured":"Ng SWK, Mitchell A, Kennedy JA, Chen WC, McLeod J, Ibrahimova N, et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature. 2016;540:433\u20137.","journal-title":"Nature"},{"key":"3064_CR37","doi-asserted-by":"publisher","first-page":"602","DOI":"10.2174\/1389202921999200625220812","volume":"21","author":"C Gao","year":"2020","unstructured":"Gao C, Zhang M, Chen L. The comparison of two single-cell sequencing platforms: BD rhapsody and 10x genomics chromium. Curr Genomics. 2020;21:602\u20139.","journal-title":"Curr Genomics"},{"key":"3064_CR38","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/s41375-023-01880-6","volume":"37","author":"Y Lu","year":"2023","unstructured":"Lu Y, Yang L, Shen M, Zhang Z, Wang S, Chen F, et al. Tespa1 facilitates hematopoietic and leukemic stem cell maintenance by restricting c-Myc degradation. Leukemia. 2023;37:1039\u201347.","journal-title":"Leukemia"},{"key":"3064_CR39","first-page":"1133","volume":"135","author":"L Zhang","year":"2020","unstructured":"Zhang L, Li J, Xu H, Shao X, Fu L, Hou Y, et al. Myc-Miz1 signaling promotes self-renewal of leukemia stem cells by repressing Cebp\u03b1 and Cebp\u03b4. Blood. 2020;135:1133\u201345.","journal-title":"Blood"},{"key":"3064_CR40","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/nature25193","volume":"553","author":"C Bahr","year":"2018","unstructured":"Bahr C, Von Paleske L, Uslu VV, Remeseiro S, Takayama N, Ng SW, et al. A Myc enhancer cluster regulates normal and leukaemic haematopoietic stem cell hierarchies. Nature. 2018;553:515\u201320.","journal-title":"Nature"},{"key":"3064_CR41","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1182\/blood.V124.21.766.766","volume":"124","author":"L von Paleske","year":"2014","unstructured":"von Paleske L, Uslu VV, Petretich M, Spitz F, Trumpp A. A novel enhancer region 1.7Mb downstream of the C-Myc gene drives its expression in hematopoietic stem and progenitor cells. Blood. 2014;124:766.","journal-title":"Blood"},{"key":"3064_CR42","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.stem.2008.09.005","volume":"3","author":"E Laurenti","year":"2008","unstructured":"Laurenti E, Varnum-Finney B, Wilson A, Ferrero I, Blanco-Bose WE, Ehninger A, et al. Hematopoietic stem cell function and survival depend on c-Myc and N-Myc activity. Cell Stem Cell. 2008;3:611\u201324.","journal-title":"Cell Stem Cell"},{"key":"3064_CR43","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.ccr.2013.01.025","volume":"23","author":"L Reavie","year":"2013","unstructured":"Reavie L, Buckley SM, Loizou E, Takeishi S, Aranda-Orgilles B, Ndiaye-Lobry D, et al. Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression. Cancer Cell. 2013;23:362\u201375.","journal-title":"Cancer Cell"},{"key":"3064_CR44","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ccr.2013.01.026","volume":"23","author":"S Takeishi","year":"2013","unstructured":"Takeishi S, Matsumoto A, Onoyama I, Naka K, Hirao A, Nakayama KI. Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence. Cancer Cell. 2013;23:347\u201361.","journal-title":"Cancer Cell"},{"key":"3064_CR45","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.molcel.2015.02.028","volume":"58","author":"LR Thomas","year":"2015","unstructured":"Thomas LR, Wang Q, Grieb BC, Phan J, Foshage AM, Sun Q, et al. Interaction with WDR5 promotes target gene recognition and tumorigenesis by MYC. Mol Cell. 2015;58:440\u201352.","journal-title":"Mol Cell"},{"key":"3064_CR46","doi-asserted-by":"publisher","first-page":"25260","DOI":"10.1073\/pnas.1910391116","volume":"116","author":"LR Thomas","year":"2019","unstructured":"Thomas LR, Adams CM, Wang J, Weissmiller AM, Creighton J, Lorey SL, et al. Interaction of the oncoprotein transcription factor MYC with its chromatin cofactor WDR5 is essential for tumor maintenance. Proc Natl Acad Sci. 2019;116:25260\u20138.","journal-title":"Proc Natl Acad Sci"},{"key":"3064_CR47","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nrc2819","volume":"10","author":"J van Riggelen","year":"2010","unstructured":"van Riggelen J, Yetil A, Felsher DW. MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer. 2010;10:301\u20139.","journal-title":"Nat Rev Cancer"},{"key":"3064_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1003628","volume":"9","author":"MK O\u2019Bryan","year":"2013","unstructured":"O\u2019Bryan MK, Clark BJ, McLaughlin EA, D\u2019Sylva RJ, O\u2019Donnell L, Wilce JA, et al. RBM5 is a male germ cell splicing factor and is required for spermatid differentiation and male fertility. PLoS Genet. 2013;9:e1003628.","journal-title":"PLoS Genet"},{"key":"3064_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39936-x","volume":"14","author":"M Mullari","year":"2023","unstructured":"Mullari M, Fossat N, Skotte NH, Asenjo-Martinez A, Humphreys DT, Bukh J, et al. Characterising the RNA-binding protein atlas of the mammalian brain uncovers RBM5 misregulation in mouse models of Huntington\u2019s disease. Nat Commun. 2023;14:4348.","journal-title":"Nat Commun"},{"key":"3064_CR50","doi-asserted-by":"publisher","first-page":"5615","DOI":"10.1158\/0008-5472.CAN-15-1824","volume":"76","author":"S Di Cecilia","year":"2016","unstructured":"Di Cecilia S, Zhang F, Sancho A, Li S, Aguil\u00f3 F, Sun Y, et al. RBM5-AS1 is critical for self-renewal of colon cancer stem-like cells. Cancer Res. 2016;76:5615\u201327.","journal-title":"Cancer Res"},{"key":"3064_CR51","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/ng1060","volume":"33","author":"S Ramaswamy","year":"2003","unstructured":"Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet. 2003;33:49\u201354.","journal-title":"Nat Genet"},{"key":"3064_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34000-6","volume":"13","author":"D Zimmerli","year":"2022","unstructured":"Zimmerli D, Brambillasca CS, Talens F, Bhin J, Linstra R, Romanens L, et al. MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling. Nat Commun. 2022;13:6579.","journal-title":"Nat Commun"},{"key":"3064_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37592-9","volume":"14","author":"RJ Austin","year":"2023","unstructured":"Austin RJ, Straube J, Halder R, Janardhanan Y, Bruedigam C, Witkowski M, et al. Oncogenic drivers dictate immune control of acute myeloid leukemia. Nat Commun. 2023;14:2155.","journal-title":"Nat Commun"},{"key":"3064_CR54","doi-asserted-by":"publisher","first-page":"3422","DOI":"10.1016\/j.cell.2025.03.047","volume":"188","author":"WJ Kim","year":"2025","unstructured":"Kim WJ, Crosse EI, De Neef E, Etxeberria I, Sabio EY, Wang E, et al. Mis-splicing-derived neoantigens and cognate TCRs in splicing factor mutant leukemias. Cell. 2025;188:3422\u20133440.e24.","journal-title":"Cell"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03064-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03064-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03064-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:43:24Z","timestamp":1790250204000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03064-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3064"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03064-4","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CL is currently an editorial board member at\n                      Genome Biology\n                      . The other authors declare that they have no other competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Human sample acquisition was approved by the Hematological Biobank, Jiangsu Biobank of Clinical Resources. The informed consent forms were approved by the Ethics Committee of Soochow University and The First Affiliated Hospital of Soochow University (ID: 2017169-3, Suzhou, China) in accordance with the Declaration of Helsinki. All mouse procedure protocols utilized in this study were in accordance with protocols approved by the Institutional Animal Care and Use Committee (IACUC) of Soochow University.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}